For EGFR-driven NSCLC, nanocarrier-assisted PROTAC delivery significantly enhanced in vivo antitumor efficacy in resistant xenografts, while co-delivery of EGFR and BRD4 degraders in a single nanoplatform achieved synergistic tumor suppression [189,190]. Here, EGFR is linked to non-small cell lung carcinoma.